Compare · BLLN vs ILMN
BLLN vs ILMN
Side-by-side comparison of BillionToOne Inc. (BLLN) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLLN and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $40.46B, about 8.3x BLLN ($4.85B).
- BLLN has been more active in the news (12 items in the past 4 weeks vs 8 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 9 for BLLN).
- Company
- BillionToOne Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $4.85B
- $40.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2000
- News (4w)
- 12
- 8
- Recent ratings
- 9
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest BLLN
- SEC Form 4 filed by BillionToOne Inc.
- SEC Form 4 filed by BillionToOne Inc.
- BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
- SEC Form 4 filed by BillionToOne Inc.
- SEC Form 4 filed by BillionToOne Inc.
- SEC Form 4 filed by BillionToOne Inc.
- BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
- Chairman and CEO Atay Oguzhan exercised 8,333 shares at a strike of $2.80 and sold $1,326,919 worth of shares (10,999 units at $120.64) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Technology Officer Tsao David exercised 3,333 shares at a strike of $2.80 and sold $416,625 worth of shares (3,333 units at $125.00) as part of a pre-agreed trading plan (SEC Form 4)
- SVP of Laboratory Operations Ten Bosch John Roderick sold $169,920 worth of shares (1,416 units at $120.00) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 22,219 units (SEC Form 4)
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)